Múltiplas infecções oportunistas em um paciente com leucemia linfocítica crônica tratado com cladribina

Revista Brasileira de Hematologia e Hemoterapia 01/2000; DOI: 10.1590/S1516-84842000000300009
Source: DOAJ

ABSTRACT Imunodeficiência humoral é uma característica intrínseca da leucemia linfocítica crônica B. A quimioterapia, principalmente quando o paciente é politratado, e em especial os análogos da purina, ampliam o espectro de susceptibilidade destes pacientes a agentes infecciosos oportunistas devido ao efeito imunossupressor celular destas drogas. Relatamos um paciente com leucemia linfocítica crônica submetido a várias linhas de quimioterapia, inclusive o 2-CdA, que apresentou múltiplas complicações infecciosas associadas a grave imunodeficiência celular.

  • [Show abstract] [Hide abstract]
    ABSTRACT: A retrospective analysis on chronic lymphocytic leukemia (CLL) patients </=55 years observed at a single institution was performed with the purpose of characterizing the clinical features and outcome of young CLL and of identifying patients with different prognostic features. Over the period from 1984 to 1994, 1,011 CLL patients (204 [20%] </=55 years of age and 807 [80%] >55 years of age) were observed. At diagnosis, younger and older patients displayed a similar distribution of clinical features, except for a significantly higher male/female ratio in younger patients (2.85 v 1. 29; P <.0001). Both groups showed an elevated rate of second primary cancers (8.3% v 10.7%), whereas the occurrence of Richter's syndrome was significantly higher in younger patients (5.9% v 1.2%; P <. 00001). Younger and older patients showed a similar overall median survival probability (10 years) but were characterized by a different distribution of causes of deaths: CLL unrelated deaths and second primary malignancies predominated in the older age group, whereas the direct effects of leukemia were prevalent in the younger age group. Although younger and older patients displayed a similar survival, the evaluation of the relative survival rates showed that the disease had a greater adverse effect on the expected survival probability of the younger population. Multivariate analysis showed that for young CLL patients only dynamic parameters, such as lymphocyte doubling time and other signs of active disease, were the independent factors that significantly influenced survival probability (P =.00001). A prolonged clinico-hematologic follow-up allowed us to identify two subsets of young CLL patients with a different prognostic outcome: a group of patients (40%) with long-lasting stable disease without treatment and an actuarial survival probability of 94% at 12 years from diagnosis and another group (60%) with progressive disease and a median survival probability of 5 years after therapy. For the latter patients, the therapeutic effect of innovative therapies with curative intents needs to be investigated in prospective, comparative clinical trials.
    Blood 07/1999; 94(2):448-54. · 9.78 Impact Factor
  • European Journal Of Haematology 11/1998; 61(4):286-7. DOI:10.1111/j.1600-0609.1998.tb01719.x · 2.41 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: 2-Chlorodeoxyadenosine (2-CdA) is associated with prolonged suppression of CD4 lymphocytes. Cases of tuberculosis or mycobacterium avium intracellulare complex (MAC) infection complicating 2-CdA administration have not been reported despite the low CD4 counts. We report a patient with Hairy Cell Leukaemia (HCL) who developed MAC infection one month following 2-CdA treatment. This patient had been previously treated with prednisone for Sweets Syndrome. It would appear that the combination of 2-CdA and prednisone predisposes patients to MAC infection, and if possible this combination of treatment should be avoided.
    Leukemia and Lymphoma 03/2000; 36(5-6):639-42. DOI:10.3109/10428190009148413 · 2.61 Impact Factor

Full-text (2 Sources)

Available from
May 17, 2014